ADVI Health Accelerates Insights with Monthly Medicare Data
ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – enabling faster, more responsive evidence generation and market insights.
What This Means for Our Clients and Partners
- Timelier Insights: Near real-time visibility into utilization and outcomes.
- Faster Evidence Generation: Accelerated health economics and outcomes research (HEOR), real-world evidence (RWE), and market access analytics aligned with evolving payer and policy needs.
- Quicker Value Demonstration: Shorter data-driven evidence cycles.
- Real-Time Market Awareness: Ongoing visibility into treatment patterns, competitive dynamics, and policy-driven shifts.
Why it Matters
In today’s evolving healthcare landscape, timing is everything. With monthly data access, ADVI enables faster, more responsive evidence generation, helping clients and partners stay ahead of change, demonstrate value sooner, and act with confidence.
Turning Data into Actionable Insights
ADVI combines timely Centers for Medicare and Medicaid Services (CMS) data with deep policy, HEOR, and market access expertise to uncover emerging trends and translate complex healthcare data into strategic insights.
ADVI Advantage
ADVI leverages high-frequency data and advanced analytics to deliver precise, timely, and actionable insights— strengthening our position as a leading partner for organizations seeking strategic, evidence-driven decision support in policy impacts, market access, and HEOR.
Medicare Drug Price Negotiation
Early Insights from Medicare Drug Price Negotiation
ADVI’s analysis of Q1 2025 and Q1 2026 data reveals how the first year of Medicare drug price negotiation is affecting patient costs, prescription spending, and Part D plan design.
Patients Saw Minimal Decreases in Out-of-Pocket Costs
Across the initial 10 IPAY 2026 drugs, patient out-of-pocket expenses decreased by an average of only $10.51 per prescription, a 6.2% decrease from Q1 2025 to Q1 2026.
Out-of-Pocket Costs Increased for Some MFP Drugs
While patient costs decreased overall, out-of-pocket costs increased for some MFP drugs from Q1 2025 to Q1 2026, including a 12.5% increase for Imbruvica.
Total Spending and Claim Volume Decreased Across MFP Drugs
From Q1 2025 to Q1 2026, total prescription spending across MFP drugs decreased by more than 60% each month, while total claim volume also declined.
Total prescription costs
Total claims
$0 Deductible Part D Plan Enrollment Dropped Significantly
The proportion of enrollees in $0 deductible Part D plans fell from 23% in 2025 to 8% in 2026, while enrollment in $590–$615 deductible plans increased from 59% to 64%.
Ready to Turn Data into Action?
Partner with ADVI Health to Turn Data into Impact—Faster
CEO insights
Related articles
Real analysis from people who’ve been there
RAND/UCLA Modified Delphi Panels
ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …
Caitlin Sheetz, MPH
June 23, 2026
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
How HEOR and Real-World Evidence Are Reshaping Decisions in 2026
By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …
FDA Proposes Down-Classification of Oncology Companion Diagnostics: A Q&A on Precision Medicine
The Food and Drug Administration (FDA) has announced a significant proposed change affecting oncology companion diagnostics (CDx) that could streamline …
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Real-World Effectiveness vs Clinical Trial Efficacy in Medicare
The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.